Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» November 2010
November 2010
FDA disputes prostate drugs' risk-cutting power
FDA disputes prostate drugs' risk-cutting power
Fierce Pharma
FDA
GSK
prostate cancer
Avodart
Merck
Proscar
Drug groups face new generics threat
Drug groups face new generics threat
FT.com
generics
Roche
Merck
JNJ
Abbott Laboratories
biogenerics
Is a Revenue Miss Coming for Eli Lilly?
Is a Revenue Miss Coming for Eli Lilly?
Motley Fool
Eli Lilly
Aegerion Pharma 3Q loss widens on higher costs
Aegerion Pharma 3Q loss widens on higher costs
Yahoo/AP
earnings
Aegerion
RNAi Is On Sale
RNAi Is On Sale
Motley Fool
RNAi
Merck
Alnylam
Pfizer
Amgen
Novartis
Eli Lilly
Roche
Biotech Calendar: Key Dates for December
Biotech Calendar: Key Dates for December
TheStreet.com
Delcath
Arena Pharmaceuticals
RXi Pharmaceuticals
Cell Therapeutics
Amgen
Incyte
Celgene
Corcept Therapeutics
Affymax
Targacept
Exelixis
Orexigen
ONYX Pharmaceuticals
Seattle Genetics
MannKind
Alimera
AstraZeneca
Human Genome Sciences
Keryx drug candidate meets late-stage study goal
Keryx drug candidate meets late-stage study goal
Yahoo/AP
Keryx
ZerenaxT
Merck Names Kenneth Frazier CEO, Clark Stays as Chairman
Merck Names Kenneth Frazier CEO, Clark Stays as Chairman
Bloomberg
Merck
Pharma CEOs
Kenneth Frazier
House Passes ‘Doc Fix’; Medicare Cuts Now Due to Kick in Jan. 1
House Passes ‘Doc Fix’; Medicare Cuts Now Due to Kick in Jan. 1
WSJ Online
Medicare
physicians
healthcare reform
Orexigen: Contrave FDA Panel Preview
Orexigen: Contrave FDA Panel Preview
TheStreet.com
FDA
advisory panels
Orexigen
Contrave
obesity
Arena Pharmaceuticals
Vivus
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »